MedPath

Ryvu Therapeutics Restructures Operations to Extend Cash Runway, Prioritizes RVU120 Blood Cancer Program

• Ryvu Therapeutics announces strategic reorganization, reducing workforce by 30% while extending cash runway to H2 2026 with €46 million in current assets and €22 million in secured grant funding.

• Company focuses resources on three ongoing Phase II trials of RVU120 in blood cancers, discontinuing new enrollment in RIVER-52 monotherapy study for AML and HR-MDS patients.

• Development continues for novel ADC programs and precision medicine platform ONCO Prime, while maintaining partnerships with Menarini, BioNTech, and Exelixis.

Ryvu Therapeutics, a clinical-stage drug discovery and development company, has announced a strategic reorganization to optimize its resources and extend its cash runway through the second half of 2026. The restructuring comes as the company sharpens its focus on advancing its lead blood cancer program RVU120 and early-stage pipeline assets.
The Polish biotech will reduce its workforce by approximately 30%, bringing total employee count to around 200. The company currently holds approximately €46 million in cash and other financial assets, supplemented by €22 million in secured non-dilutive grant funding.

Strategic Focus on RVU120 Clinical Program

The company is prioritizing three Phase II clinical trials of RVU120, while strategically discontinuing new patient enrollment in one study. The ongoing trials include:
  • RIVER-81: Combination therapy with venetoclax in acute myeloid leukemia (AML)
  • POTAMI-61: Monotherapy and combination with ruxolitinib in myelofibrosis
  • REMARK: Monotherapy in lower-risk myelodysplastic syndromes (LR-MDS)
The Phase II RIVER-52 study, investigating RVU120 monotherapy in AML and high-risk MDS patients, will stop enrolling new patients but continue treatment for currently enrolled participants. This decision follows recent data analysis and advisory board recommendations in February 2025.
"We remain focused on advancing our first-in-class clinical blood cancer program RVU120, as well as promising early-stage assets," stated Paweł Przewięźlikowski, Chief Executive Officer and largest shareholder of Ryvu. "Considering our cash position, revenue projections, cost structure and the demanding market environment, we decided to optimize expenses so that the company has sufficient cash runway to generate key data for RVU120 and the preclinical pipeline."

Advancing Early-Stage Programs and Partnerships

Ryvu continues to advance its preclinical portfolio through two main strategies:
  1. ONCO Prime Platform: Development of novel small molecule precision medicines, including synthetic lethality targets, supported by a PLN 26 million grant from the Polish Agency for Enterprise Development.
  2. Antibody-Drug Conjugates (ADCs): Focus on next-generation novel payloads, including the repositioning of their WRN program as an ADC payload. This research is backed by approximately PLN 13 million in grant funding.
The company maintains active partnerships with:
  • Menarini: Phase II JASPIS-01 study of dapolsertib in DLBCL
  • BioNTech: Multi-target research collaboration in small molecule immune modulators
  • Exelixis: Development of ADCs with STING payloads

Clinical Development Timeline

RVU120's next data update is scheduled for Q2 2025, while RVU305, the company's PRMT5 inhibitor for solid tumors, is progressing through IND/CTA-enabling studies with expected completion in H2 2025.
The restructuring positions Ryvu to achieve significant clinical milestones while maintaining financial stability through key data readouts that could support future partnering opportunities or internal development programs.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Inventiva Restructures to Focus on MASH Drug Development, Reports €96.6M Year-End Cash Position

Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.
Company reports €96.6 million cash position at 2024 year-end, securing operations until Q3 2025, with potential additional funding of €116 million expected in Q2 2025.

Ventyx Biosciences Advances NLRP3 Inhibitor Portfolio with Phase 2 Trials

Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025.
A Phase 2 trial of VTX2735 for recurrent pericarditis is expected to begin in January, with topline results anticipated in the second half of 2025.

Werewolf Therapeutics Announces 2025 Milestones for IL-2 and IL-12 INDUKINE Programs

Werewolf Therapeutics anticipates sharing preliminary monotherapy data for WTX-124 in H1 2025, potentially guiding regulatory engagement for accelerated approval.
A Phase 1/2 clinical trial of WTX-330, an IL-12 INDUKINE molecule, is expected to begin in Q1 2025, targeting immunotherapy-resistant cancers.

Krystal Biotech and CRISPR Therapeutics Announce Key Updates in Gene Therapy Programs

Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.
Krystal Biotech's KB407 for cystic fibrosis received full sanctioning for its Phase 1 CORAL-1 study, with interim molecular data expected mid-2025.

Perspective Therapeutics and PMV Pharma Provide Clinical Trial Updates

Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.
Perspective Therapeutics plans to initiate therapeutic dosing of PSV359, a FAP-α-targeted radiopharmaceutical, with potential study enrollment around mid-2025.

Ryvu Therapeutics Provides Update on RVU120 Phase II Program

Ryvu Therapeutics has successfully launched four Phase II clinical studies (RIVER-52, RIVER-81, POTAMI-61, and REMARK) for RVU120, with key efficacy analyses expected in H1 2025.
Enrollment is accelerating across all studies, with nearly 100 patients anticipated to be dosed by year-end, and the pace of recruitment has significantly increased since September 2024.

Ryvu Therapeutics Accelerates RVU120 Clinical Trials and Reports Q3 2024 Financial Results

Ryvu Therapeutics reported USD 18.6 million in operating revenues for Q1-Q3 2024, compared to USD 11.9 million in the same period last year, driven by pipeline advancements.
Enrollment in RVU120 Phase II studies (RIVER-52, RIVER-81, REMARK) has accelerated due to increased clinical site activation, with 66 sites active as of October 31.

Inventiva's Lanifibranor Phase III Trial NATiV3 Progresses in MASH/NASH Treatment

Inventiva's NATiV3 trial for MASH/NASH treatment has enrolled over 85% of the targeted patients in the main cohort, with statistical powering expected to exceed 95% for both doses.
Blinded analyses of NATiV3 patients suggest positive biomarker evolution, aligning with Phase IIb NATIVE study results, and weight gain stabilizes after 24-36 weeks.

Ryvu Therapeutics Advances RVU305 PRMT5 Inhibitor to Preclinical Development; Reports Positive Financials and Clinical Trial Updates

Ryvu Therapeutics is advancing RVU305, a PRMT5 inhibitor, into preclinical development with IND/CTA filing targeted for H2 2025.
The company's RVU120 Phase II studies are progressing, with initial data expected at the ASH 2024 conference in December.

Repare Therapeutics Prioritizes Clinical Oncology Pipeline, Streamlining Operations

Repare Therapeutics is focusing on its clinical-stage oncology programs, including lunresertib, camonsertib, RP-1664, and RP-3467, to maximize value for patients and shareholders.
The company plans to reduce its workforce by approximately 25%, mainly from the preclinical group, to extend its cash runway into the second half of 2026.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy